# Novartis India (NSE: NOVARTIND) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/NOVARTIND · Pivot · prices to 21 Oct 2026

Novartis India (NSE: NOVARTIND) closed at ₹1,818.10 on 21 Oct 2026. With a market capitalisation of ₹3,429 Cr, it ranks 892nd by market cap among the 3,928 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

Its return on equity was 12.9% in FY25. Its 52-week range is ₹950.00 (24 Apr 2026) to ₹2,588.80 (10 Sep 2026); the last close is 29.8% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹104 Cr (+18.6% year on year) and net profit ₹32 Cr (+16.6%), on a standalone basis. Promoters held 70.68% of the company as of 31 Jul 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹1,818.10 |
| Market cap | ₹3,429 Cr |
| ROE | 12.9% (FY25) |
| ROCE | 16.3% (FY25) |
| Debt to equity | 0 |
| 52-week high | ₹2,588.80 (10 Sep 2026) |
| 52-week low | ₹950.00 (24 Apr 2026) |

## Quarterly results (₹ crore, standalone)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹104 Cr | +18.6% | ₹32 Cr | +16.6% | ₹13.05 |
| Q4 FY26 | ₹91 Cr | +8.0% | ₹25 Cr | −13.8% | ₹10.23 |
| Q3 FY26 | ₹86 Cr | −7.6% | ₹16 Cr | −36.8% | ₹6.52 |
| Q2 FY26 | ₹90 Cr | +3.7% | ₹24 Cr | +18.7% | ₹9.81 |
| Q1 FY26 | ₹88 Cr | −5.1% | ₹28 Cr | +7.3% | ₹11.19 |
| Q4 FY25 | ₹84 Cr | +3.3% | ₹29 Cr | +99.6% | ₹11.87 |
| Q3 FY25 | ₹93 Cr | +10.0% | ₹25 Cr | −4.2% | ₹10.31 |
| Q2 FY25 | ₹87 Cr | +10.6% | ₹20 Cr | −13.8% | ₹8.27 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹356 Cr | ₹101 Cr |
| FY24 | ₹335 Cr | ₹85 Cr |
| FY23 | ₹379 Cr | ₹103 Cr |
| FY22 | ₹400 Cr | −₹4 Cr |
| FY21 | ₹381 Cr | ₹21 Cr |
| FY20 | ₹438 Cr | ₹10 Cr |

## Shareholding (31 Jul 2026)

- Promoters: 70.68%
- Foreign institutions: 0.15%
- Domestic institutions: 1.39%
- Non-institutions: 27.78%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [RPG Life Sciences](https://app.pivotnow.in/stock/RPGLIFE) | — | ₹3,766 Cr | — | — |
| [Gufic Biosciences](https://app.pivotnow.in/stock/GUFICBIO) | — | ₹3,562 Cr | — | — |
| [SMS Pharmaceuticals](https://app.pivotnow.in/stock/SMSPHARMA) | — | ₹3,545 Cr | — | — |
| [Aarti Drugs](https://app.pivotnow.in/stock/AARTIDRUGS) | — | ₹3,380 Cr | — | — |
| [Panacea Biotec](https://app.pivotnow.in/stock/PANACEABIO) | — | ₹3,285 Cr | — | — |
| [Unichem Laboratories](https://app.pivotnow.in/stock/UNICHEMLAB) | — | ₹3,128 Cr | — | — |

## Questions and answers

### What is the share price of Novartis India today?

Novartis India (NSE: NOVARTIND) last closed at ₹1,818.10 on 21 Oct 2026. Its 52-week high is ₹2,588.80 and its 52-week low is ₹950.00.

### What is the market cap of Novartis India?

Novartis India's market capitalisation is ₹3,429 Cr (₹3,429 Cr) at the — close, ranking 892nd among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Novartis India?

Return on equity was 12.9% in FY25 and return on capital employed was 16.3% in FY25 (standalone figures).

### Is Novartis India a debt-free company?

Novartis India is close to debt-free: its debt-to-equity ratio was 0 in FY25.

### What were Novartis India's latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Novartis India reported revenue of ₹104 Cr, +18.6% year on year, and net profit of ₹32 Cr, +16.6% year on year.

### What is the shareholding pattern of Novartis India?

As of 31 Jul 2026: promoters 70.68%, foreign institutions 0.15%, domestic institutions 1.39%, non-institutions 27.78%.

### Who are Novartis India's competitors?

The listed Pharma & Healthcare companies closest to Novartis India by market cap are RPG Life Sciences, Gufic Biosciences, SMS Pharmaceuticals, Aarti Drugs, Panacea Biotec and Unichem Laboratories.

### Is Novartis India a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Novartis India's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on NOVARTIND against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.